Evidence map›Paper›PMID 39052574›Full record

ArticlePloS one2024

Botanical formulation HX110B ameliorates PPE-induced emphysema in mice via regulation of PPAR/RXR signaling pathway.

Soojin Lee, Chang Hyung Lee, Jungkyu Lee, Yoonseon Jeong, Jong-Hyung Park, In-Jeong Nam, Doo Suk Lee, Hyun Myung Lee, Soo-Yeon Ahn, Eujung Kim and 3 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Soojin LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Chang Hyung LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Jungkyu LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Yoonseon JeongR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Jong-Hyung ParkR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
In-Jeong NamR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Doo Suk LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Hyun Myung LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Soo-Yeon AhnR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Eujung KimR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Seungyeon JeongR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Seung-Shin YuR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.
Wonwoo LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, Korea.ORCID 0000-0003-4186-8888

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD), an inflammatory lung disease, causes approximately 3 million deaths each year; however, its pathological mechanisms are not fully understood. In this study, we examined whether HX110B, a mixture of Taraxacum officinale, Dioscorea batatas, and Schizonepeta tenuifolia extracts, could suppress porcine pancreatic elastase (PPE)-induced emphysema in mice and its mechanism of action. The therapeutic efficacy of HX110B was tested using a PPE-induced emphysema mouse model and human bronchial epithelial cell line BEAS-2B. In vivo data showed that the alveolar wall and air space expansion damaged by PPE were improved by HX110B administration. HX110B also effectively suppresses the expression levels of pro-inflammatory mediators including IL-6, IL-1β, MIP-2, and iNOS, while stimulating the expression of lung protective factors such as IL-10, CC16, SP-D, and sRAGE. Moreover, HX110B improved the impaired OXPHOS subunit gene expression. In vitro analysis revealed that HX110B exerted its effects by activating the PPAR-RXR signaling pathways. Overall, our data demonstrated that HX110B could be a promising therapeutic option for COPD treatment.

Indexed as

Pancreatic ElastasePlant ExtractsSignal TransductionAnimalsCell LineDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLPeroxisome Proliferator-Activated ReceptorsPulmonary Disease, Chronic ObstructivePulmonary EmphysemaSwinePancreatic ElastasePeroxisome Proliferator-Activated ReceptorsPlant Extracts

Identifiers

PMID39052574
PMCPMC11271920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.